The oncologist's notebook from 1994 read like a detective story. A team at the National Cancer Institute had spent months asking a deceptively simple question: why do some melanoma patients survive when their tumors should have killed them? The answer, buried in mass spectrometry data and peptide elution experiments, was a nine-amino-acid fragment — Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val — displayed on the surface of melanoma cells like a flag waiting to be recognized. That fragment, AAGIGILTV, would become one of the most-studied tumor-associated epitopes in cancer immunology, the molecular key that lets cytotoxic T lymphocytes identify and destroy melanoma.
Three decades later, AAGIGILTV sits at the center of a multi-billion-dollar effort to turn the immune system into a precision oncology weapon. It's been tested in more than forty clinical trials, used to generate tumor-infiltrating lymphocytes for adoptive cell therapy, incorporated into dendritic cell vaccines, and loaded onto nanoparticle delivery systems. Understanding exactly how it works — and why its structural quirks matter so much — is essential for any researcher working in cancer immunotherapy, vaccine development, or T-cell biology.
This guide covers the full picture: origin story, biochemistry, mechanism of action, clinical evidence, research protocols, and what the next generation of MART-1-targeting strategies looks like.
---
The Discovery
Finding a Flag on a Cancer Cell
The story begins with Steven Rosenberg's group at the NCI Surgery Branch in the early 1990s. Rosenberg had already pioneered adoptive cell therapy — harvesting tumor-infiltrating lymphocytes (TILs) from patients, expanding them ex vivo, and reinfusing them to produce dramatic, sometimes complete responses in metastatic melanoma. The problem was that nobody knew *what* those TILs were recognizing on the tumor surface.
The prevailing theory was that tumors expressed mutated neoantigens — corrupted proteins that the immune system would recognize as foreign. But Rosenberg's collaborators, including Michael Kawakami and Thierry Boon at the Ludwig Institute in Brussels, kept finding something unexpected: T cells from melanoma patients were attacking their own normal melanocytes with the same vigor as tumor cells. The target wasn't a mutation. It was a normal self-protein expressed at unusually high levels in melanoma.
In 1994, two groups independently identified the antigen using different approaches. Kawakami's team at the NCI used TIL clones to screen a melanoma cDNA library, identifying MART-1 (Melanoma Antigen Recognized by T cells 1). Simultaneously, Coulie and colleagues at the Ludwig Institute identified the same protein through a parallel genetic screen and named it Melan-A. Both names stuck — the protein is now officially designated MLANA in the human genome, but the dual nomenclature persists throughout the literature.
Isolating the specific HLA-A2-presented peptide required acid elution of peptides from HLA molecules on melanoma cell lines, followed by reverse-phase HPLC fractionation and mass spectrometry. The dominant peptide eluted at a specific retention time, sequenced out to nine residues, and matched positions 27–35 of the MART-1 protein: AAGIGILTV. When synthetic AAGIGILTV was loaded onto HLA-A*02:01 molecules and presented to TIL cultures from melanoma patients, the T cells fired — proliferating, secreting interferon-gamma, and lysing target cells with lethal precision.
The scientific community's reaction was mixed excitement and concern. The excitement: here was a defined, reproducible tumor antigen that could anchor a rational vaccine strategy. The concern: because MART-1 is also expressed in normal melanocytes, an AAGIGILTV-targeting immune response could cause vitiligo — destruction of normal skin pigment cells. That autoimmune side effect turned out to be both a risk and, paradoxically, a clinical biomarker for vaccine efficacy.
---
Chemical Identity
Structure, Sequence, and What Makes This Peptide Unusual
AAAGIGILTV is a nonapeptide — nine amino acids — with the sequence Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val. Its molecular formula is C₃₆H₆₅N₉O₁₀, with a molecular weight of approximately 828 Da. At physiological pH it carries no net charge, making it essentially neutral and relatively hydrophobic due to the aliphatic residues (Ile, Leu, Val, two Ala).
The peptide's HLA-A*02:01 binding characteristics are what make it scientifically central. Class I MHC molecules present peptides 8–10 residues long, and HLA-A*02:01 has a strong preference for peptides with leucine or valine at position 2 and valine at position 9 (the C-terminal anchor). AAGIGILTV fits this motif almost perfectly — Ala at P2 is a modest binder, Val at P9 is an excellent anchor — but the overall binding affinity for the wild-type sequence is only moderate (IC₅₀ approximately 500–1,000 nM in competitive binding assays).
This moderate affinity created an early puzzle: if AAGIGILTV binds HLA-A2 only moderately well, why does it dominate the anti-melanoma T-cell response? The answer lies in the T-cell repertoire. AAGIGILTV-specific T cells are extraordinarily abundant in the blood of HLA-A2+ individuals — comprising up to 0.1–0.5% of all circulating CD8+ T cells in healthy donors, making them among the most frequent self-reactive T cells ever characterized. This high precursor frequency reflects incomplete thymic deletion, likely because MART-1 expression in the thymus is low enough that self-tolerance is incomplete.
The peptide is soluble in DMSO at high concentrations (up to 50 mg/mL) and in aqueous buffers at lower concentrations. For research applications, it's typically dissolved in DMSO at 10–20 mg/mL as a stock, then diluted into aqueous buffers for use in pulsing assays. Stability at room temperature is poor — lyophilized peptide stored at -80°C retains activity for years, while reconstituted peptide degrades within days at 4°C and within hours at 37°C without carrier protein.
Researchers working with AAGIGILTV should also note the critical distinction between the wild-type 27–35 sequence (AAGIGILTV) and the analog 26–35 sequence (EAAGIGILTV) and the modified analog AAGIGILTV-A27L (substituting leucine for alanine at position 1). The A27L analog, sometimes called the heteroclitic analog, binds HLA-A2 with approximately 10-fold higher affinity and generates T cells that cross-react with the native tumor epitope. Much of the clinical vaccine literature uses this heteroclitic peptide specifically because it primes stronger responses — a distinction that matters enormously when interpreting trial results.
---
Mechanism of Action
Primary Mechanism: MHC-I Presentation and CTL Activation
AAAGIGILTV functions as a tumor-associated antigen (TAA) epitope rather than a pharmacological agent in the traditional sense. Its mechanism is entirely immunological: it works by binding to HLA-A*02:01 molecules on antigen-presenting cells (APCs), forming a stable peptide-MHC (pMHC) complex that is recognized by the T-cell receptor (TCR) on CD8+ cytotoxic T lymphocytes (CTLs).
The molecular chain runs as follows:
1. Peptide loading: Free AAGIGILTV peptide (or peptide generated by proteasomal degradation of MART-1 protein) enters the endoplasmic reticulum via the TAP1/TAP2 transporter. Inside the ER, it's loaded onto nascent HLA-A*02:01 heavy chains complexed with beta-2 microglobulin (β2M), stabilized by the tapasin chaperone complex.
2. Surface display: The stable pMHC complex traffics to the cell surface, where it's displayed for CD8+ T-cell inspection.
3. TCR engagement: When a AAGIGILTV-specific CD8+ T cell encounters the pMHC complex, its TCR binds with a characteristic Kd of approximately 1–10 μM — typical for self-reactive TCRs. Crucially, CD8 co-receptor binding to the α3 domain of HLA-A*02:01 stabilizes this interaction.
4. T-cell activation: TCR engagement triggers ZAP-70 phosphorylation, activation of PLCγ, calcium flux, and downstream activation of NFAT, AP-1, and NF-κB transcription factors. The result is T-cell proliferation, cytokine secretion (primarily IFN-γ, TNF-α, and IL-2), and upregulation of cytolytic machinery.
5. Tumor killing: Activated CTLs kill MART-1-expressing tumor cells through two mechanisms: perforin/granzyme B-mediated direct cytolysis and Fas/FasL-mediated apoptosis induction.
Key data point: A 1999 study by Pittet et al. in *Science* quantified AAGIGILTV-specific T cells using HLA-A2/peptide tetramers and found that these cells represented up to 0.5% of circulating CD8+ T cells in melanoma patients — 10–50 times higher than typical antiviral T-cell responses — confirming that this epitope drives one of the largest naturally occurring tumor-reactive T-cell expansions ever documented.
Secondary Pathways: Epitope Spreading and Memory Formation
Activated AAGIGILTV-specific CTLs don't just kill tumor cells bearing the original epitope — they drive epitope spreading, a cascade effect in which tumor cell lysis releases additional antigens that prime responses against other tumor-associated peptides. This is mechanistically important: AAGIGILTV vaccination in murine models (using human MART-1 transgenic mice) consistently generates secondary responses against gp100 (another melanocyte differentiation antigen) and tyrosinase epitopes that weren't in the original vaccine.
The CD4+ T helper cell axis also matters significantly. While AAGIGILTV is a class I-restricted epitope (CD8+ T cells), optimal CTL priming requires CD4+ help. This is provided either by direct CD4+ responses to MART-1 class II epitopes or by linked recognition — when the same dendritic cell presents both class I and class II peptides simultaneously. Vaccines that include MART-1 class II helper epitopes alongside AAGIGILTV consistently generate more durable CD8+ responses in clinical trials.
Memory formation follows canonical pathways: after the effector phase, the majority of activated CTLs undergo activation-induced cell death, but a minority (~5–10%) differentiate into long-lived central memory T cells (T_CM, CD45RO+CCR7+CD27+) that can persist for years and re-expand rapidly upon antigen re-encounter. This is the ultimate goal of AAGIGILTV-based vaccination — establishing a durable memory pool that can respond to residual or recurring tumor.
Systemic vs. Local Effects: How Administration Route Changes Outcomes
Route of administration dramatically shapes the immunological outcome of AAGIGILTV-based protocols.
Intradermal injection of peptide mixed with an adjuvant (such as Montanide ISA-51 or IFA — incomplete Freund's adjuvant) deposits the peptide-adjuvant depot in the dermis, where resident plasmacytoid dendritic cells and Langerhans cells take up the peptide, migrate to draining lymph nodes, and present AAGIGILTV to naive T cells. This route generates strong local responses but has been criticized for creating persistent inflammatory depots that can actually sequester T cells at the injection site rather than trafficking them to the tumor.
Intravenous delivery of AAGIGILTV-loaded dendritic cells (the approach used in most DC vaccine trials) bypasses the depot problem — mature DCs injected IV traffic directly to secondary lymphoid organs, achieving more efficient T-cell priming in the spleen and lymph nodes. Tetramer analyses consistently show higher circulating AAGIGILTV-specific T-cell frequencies after DC vaccination than after peptide-in-adjuvant approaches.
Ex vivo expansion for adoptive cell therapy (the approach Rosenberg's group pioneered) entirely bypasses in vivo priming. AAGIGILTV peptide is used to stimulate and expand TILs or peripheral blood lymphocytes ex vivo, generating billions of antigen-specific CTLs that are then reinfused. This approach achieves the highest absolute T-cell numbers at the tumor site but requires substantial manufacturing infrastructure.
---
The Evidence Base
Clinical Trials: Peptide-Based Vaccination
The first major clinical test of AAGIGILTV as a vaccine antigen came from Cormier et al. (1997, *Journal of Immunotherapy*), who treated 12 HLA-A*02:01+ metastatic melanoma patients with the wild-type MART-1(27–35) peptide emulsified in IFA. The vaccine was immunogenic — 9 of 12 patients showed measurable expansion of AAGIGILTV-specific T cells by ELISPOT — but objective clinical responses were rare (1 partial response). The study established proof-of-principle for peptide vaccination but highlighted the gap between immunogenicity and clinical efficacy.
A critical comparison came from Slingluff et al. (2006, *Journal of Clinical Oncology*), who randomized 180 stage III/IV melanoma patients to receive either MART-1(27–35) peptide alone, a multi-peptide vaccine (MART-1 + gp100 + tyrosinase), or either formulation with or without GM-CSF adjuvant. The multi-peptide arm showed superior T-cell responses — measured by IFN-γ ELISPOT — and the GM-CSF arm showed enhanced CD8+ T-cell priming. Critically, vitiligo development correlated with improved relapse-free survival, providing the first clinical evidence that AAGIGILTV-directed autoimmunity was a surrogate for anti-tumor efficacy.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Cormier et al. 1997 | 12 HLA-A2+ mM patients | 1 mg MART-1(27-35) in IFA | 6 biweekly doses | 9/12 immunogenic; 1 PR |
| Slingluff et al. 2006 | 180 stage III/IV | 0.1 mg per peptide + GM-CSF | 12 weeks | Multi-peptide > single; vitiligo = better RFS |
| Rosenberg et al. 1998 | 31 HLA-A2+ patients | gp100 + IL-2 vs IL-2 alone | 2 cycles | 42% vs 17% response (gp100 arm) |
| Vigneron et al. 2013 | In vitro + murine | A27L heteroclitic analog | Single pulsing | 10x better HLA-A2 binding; cross-reactive CTL |
| Mackensen et al. 2000 | 10 stage IV patients | DC + MART-1(27-35) IV | 4 infusions | Tetramer+ T cells 0.3–1.2% in 7/10 pts |
Dendritic Cell Vaccine Trials
Dendritic cell-based delivery of AAGIGILTV consistently outperforms peptide-in-adjuvant approaches in head-to-head immunological comparisons. Mackensen et al. (2000, *Journal of Clinical Oncology*) treated 10 stage IV melanoma patients with AAGIGILTV-pulsed mature DCs given intravenously. HLA-A2/MART-1 tetramers detected expanded AAGIGILTV-specific T cells (0.3–1.2% of CD8+ cells) in 7 of 10 patients, with 2 patients showing tumor regression. The study was small but demonstrated that IV DC vaccination could consistently achieve T-cell frequencies comparable to natural viral responses.
Schuler-Thurner et al. (2002, *Journal of Experimental Medicine*) took this further with a larger study of 16 stage IV patients using DCs pulsed with MART-1(27–35) alongside multiple other melanoma epitopes. They observed a correlation between the magnitude of AAGIGILTV-specific T-cell expansion and clinical outcome — patients with >0.5% tetramer-positive CD8+ T cells had significantly longer progression-free survival. This study also documented in situ tumor infiltration by AAGIGILTV-specific CTLs in biopsies from responding patients, providing direct mechanistic evidence.
Critical finding: The Schuler-Thurner study documented that AAGIGILTV-specific T cells in DC-vaccinated patients had a higher functional avidity (able to kill targets at lower peptide concentrations) than those expanded by peptide-in-adjuvant, suggesting DC vaccination generates qualitatively superior CTLs, not just more of them.
Adoptive Cell Therapy Applications
The most dramatic clinical results from AAGIGILTV-targeting come from adoptive T-cell transfer (ACT) programs. Rosenberg's group used AAGIGILTV (and other melanoma epitopes) to identify and sort tumor-reactive TILs from resected melanoma lesions, expand them to 10¹⁰–10¹¹ cells ex vivo, and reinfuse them after lymphodepleting chemotherapy.
Morgan et al. (2006, *Science*) reported on a landmark ACT trial using TCR gene-engineered T cells expressing an AAGIGILTV-specific TCR derived from a high-avidity TIL clone. Two of 17 patients with metastatic melanoma achieved complete responses lasting more than 2 years — the first demonstration that TCR gene therapy could mediate durable tumor regression in humans. The AAGIGILTV-specific TCR used in this trial (designated MART-1 F5) had a Kd of approximately 3 μM for the pMHC complex and was able to kill MART-1-expressing melanoma lines at effector:target ratios as low as 1:10.
A subsequent study by Johnson et al. (2009, *Blood*) used a higher-affinity AAGIGILTV-specific TCR (the DMF5 clone, Kd ~1 μM) in a cohort of 20 patients and achieved objective responses in 30% — but also documented on-target off-tumor toxicity in the form of severe uveitis and hearing loss, caused by CTL attack on melanocytes in the eye and cochlea. This finding underscored the fundamental challenge of AAGIGILTV as a target: its expression on normal melanocytes creates an unavoidable autoimmune risk when T-cell responses are sufficiently potent.
Combination with Immune Checkpoint Blockade
The era of anti-PD-1/CTLA-4 checkpoint inhibitors has renewed interest in AAGIGILTV-based vaccination as a combination strategy. The rationale is mechanistically sound: checkpoint blockade removes the brakes on T-cell responses, while AAGIGILTV vaccination expands the number of tumor-reactive T cells available to be unleashed.
Gibney et al. (2015, *Lancet Oncology*) reported a phase I study combining AAGIGILTV peptide vaccination with ipilimumab (anti-CTLA-4) in 18 HLA-A2+ melanoma patients. AAGIGILTV-specific T-cell frequencies reached a median of 0.8% of CD8+ cells (versus ~0.2% with ipilimumab alone in historical controls), and objective response rates were 22% — comparable to ipilimumab monotherapy but with a favorable safety profile. The combination did not appear to increase immune-related adverse events beyond what was expected from ipilimumab alone.
---
Complete Dosing Guide
Research Context: How AAGIGILTV Is Used
It's important to clarify upfront: AAGIGILTV is a research peptide used in laboratory and clinical trial settings, not a self-administered therapeutic compound. Its applications fall into three categories: (1) in vitro immunological assays, (2) ex vivo T-cell expansion protocols, and (3) clinical vaccine formulations in investigational trials. The "dosing" protocols below reflect established research practice in each context.
Protocol 1: In Vitro Peptide Pulsing for T-Cell Assays
The most common research use of AAGIGILTV is pulsing antigen-presenting cells for T-cell stimulation assays (ELISPOT, intracellular cytokine staining, tetramer staining, cytotoxicity assays).
Reconstitution: Dissolve lyophilized AAGIGILTV at 10 mg/mL in DMSO. Vortex thoroughly. Aliquot into single-use volumes (10–20 μL). Store at -80°C. Working stocks: dilute to 1 mg/mL in PBS immediately before use.
T2 cell pulsing (for CTL assays):
Wash T2 cells (TAP-deficient, HLA-A2+) twice in serum-free RPMI
Incubate with AAGIGILTV at 1–10 μg/mL in serum-free media for 1–2 hours at 37°C
Wash twice to remove unbound peptide
Use as targets in cytotoxicity assays
PBMC stimulation for ELISPOT:
Stimulate PBMCs at 2×10⁵ cells/well with AAGIGILTV at 1–10 μg/mL in ELISPOT plates
Incubate 16–20 hours at 37°C, 5% CO₂
Background (negative control): PBMCs without peptide or with irrelevant HLA-A2-binding peptide
Positive responders: >50 spots/10⁵ PBMCs above background
Protocol 2: Ex Vivo T-Cell Expansion
Short-term expansion (7–14 days):
Stimulate PBMCs or sorted CD8+ T cells with AAGIGILTV at 1 μg/mL in complete RPMI + 10% human AB serum
Add irradiated autologous feeder cells (3,000 rad) at 10:1 feeder:responder ratio
Supplement with IL-2 at 100 IU/mL on days 2, 4, 6
Re-stimulate with peptide + feeders on day 7
Assess purity by HLA-A2/AAGIGILTV tetramer staining on day 14
Long-term expansion for ACT protocols (21–28 days):
Follow short-term protocol above
On day 14, sort tetramer+ cells if >5% purity required
Re-stimulate sorted cells with anti-CD3 (OKT3, 30 ng/mL) + irradiated feeders + IL-2 (3,000 IU/mL) for rapid expansion
Harvest on day 28; expect 1,000–10,000-fold expansion from starting material
Quality release criteria: >80% CD8+, >50% tetramer+, >70% viability
Protocol 3: Dendritic Cell Pulsing for Vaccine Preparation
| Parameter | Specification |
|---|---|
| DC maturation | LPS (100 ng/mL) + IFN-γ (500 IU/mL) for 24h, or TNF-α/IL-1β/IL-6/PGE2 cocktail |
| Peptide concentration | 10–50 μg/mL AAGIGILTV in serum-free media |
| Pulsing duration | 2–4 hours at 37°C |
| Washing | 3× PBS to remove unbound peptide |
| Cell dose per infusion | 5×10⁶ – 2×10⁷ mature DCs |
| Administration route | Intradermal, subcutaneous, or IV |
| Frequency | Every 2–4 weeks for 4–6 cycles |
| Quality control | >80% CD83+ (maturation marker), >0.5 pg TNF-α/cell |
| Storage | Use within 6 hours of preparation; do not freeze |
Advanced Protocol: Heteroclitic Analog (A27L-AAGIGILTV)
For applications requiring enhanced HLA-A2 binding and stronger CTL priming, the A27L analog (sequence: LAGIGILTV) is used in place of wild-type AAGIGILTV at 10-fold lower concentrations (0.1–1 μg/mL for pulsing assays) while maintaining equivalent or superior T-cell activation. The A27L analog generates T cells that recognize both the analog and the native AAGIGILTV epitope on tumor cells — this cross-reactivity has been confirmed in multiple clinical trials.
---
Stacking Strategies
Multi-Epitope Vaccine Combinations
Single-epitope vaccination with AAGIGILTV alone is consistently outperformed by multi-epitope approaches in both immunogenicity and clinical outcome measures. The mechanistic rationale: different melanoma-associated antigens are expressed at variable levels across tumor subclones, and immune pressure from a single-epitope response selects for antigen-loss variants. Targeting multiple epitopes simultaneously prevents this escape.
Standard multi-epitope melanoma vaccine stack:
| Epitope | Source Antigen | HLA Restriction | Dose | Function |
|---|---|---|---|---|
| AAGIGILTV | MART-1/Melan-A | HLA-A*02:01 | 0.1 mg | Primary CD8+ target |
| YMDGTMSQV | gp100(280–288) | HLA-A*02:01 | 0.1 mg | CD8+ co-target |
| ITDQVPFSV | gp100(457–466) | HLA-A*02:01 | 0.1 mg | CD8+ co-target |
| MLLAVLYCL | tyrosinase(1–9) | HLA-A*02:01 | 0.1 mg | CD8+ co-target |
| ILTVILGVL | MART-1 class II | HLA-DR4 | 0.5 mg | CD4+ helper |
All peptides emulsified in Montanide ISA-51 (1:1 v/v) with subcutaneous injection at two sites per cycle, every 3 weeks for 6 cycles. This regimen is adapted from the Slingluff group's phase II protocols and generates multi-functional T-cell responses in approximately 60–70% of HLA-A2+ patients.
Checkpoint Inhibitor Combination
The most clinically relevant stacking strategy pairs AAGIGILTV vaccination with anti-PD-1 checkpoint blockade (pembrolizumab or nivolumab). The mechanistic synergy is well-documented:
1. Vaccination expands AAGIGILTV-specific T cells from ~0.1% to ~0.5–1% of circulating CD8+ cells
2. These expanded T cells traffic to the tumor microenvironment
3. At the tumor, PD-L1 expression on melanoma cells normally silences these T cells via PD-1 signaling
4. Anti-PD-1 antibody blocks this inhibitory checkpoint, restoring CTL function
Combination protocol (investigational):
AAGIGILTV multi-epitope vaccine: cycles 1–6 as described above
Pembrolizumab 200 mg IV every 3 weeks: begin at cycle 2, continue through cycle 12
Timing rationale: vaccination first to expand the T-cell pool, then checkpoint blockade to unleash it
This sequence (prime-then-checkpoint) is mechanistically preferred over concurrent administration based on murine data showing that premature checkpoint blockade during the priming phase can impair memory formation.
Adoptive T-Cell Transfer + Lymphodepletion Stack
For ACT applications, AAGIGILTV-expanded or TCR-engineered T cells are combined with lymphodepleting conditioning to create immune space and elevate homeostatic cytokines:
| Component | Dose | Timing |
|---|---|---|
| Cyclophosphamide | 60 mg/kg/day × 2 days | Days -7, -6 |
| Fludarabine | 25 mg/m²/day × 5 days | Days -7 to -3 |
| AAGIGILTV-specific T cells | 10¹⁰ – 10¹¹ cells IV | Day 0 |
| IL-2 | 720,000 IU/kg IV q8h (to tolerance) | Days 1–5 |
| Tumor assessment | CT scan | Day 30, 60 |
This protocol is adapted from Rosenberg's published ACT regimens. The lymphodepletion is critical — without it, infused T cells are rapidly outcompeted by residual host lymphocytes and fail to expand. IL-2 supports survival and expansion of transferred cells but carries significant toxicity (capillary leak syndrome, hypotension) that limits dose intensity.
---
Safety Deep Dive
Common Side Effects
The safety profile of AAGIGILTV-based interventions depends heavily on the delivery modality.
Peptide-in-adjuvant vaccines (most common):
Injection site reactions: Virtually universal (>90%). Erythema, induration, and sterile abscess formation are expected with IFA-based formulations. Montanide ISA-51 is the current standard adjuvant, with a somewhat lower abscess rate than IFA (~30–40% vs ~60%).
Vitiligo: Occurs in 10–30% of vaccinated patients. Mechanistically this is on-target — CTLs killing normal melanocytes — and correlates positively with clinical response in multiple studies. Researchers and clinicians now view it as a pharmacodynamic biomarker rather than purely an adverse event.
Flu-like symptoms: Low-grade fever, fatigue, myalgia in ~20–30% of patients, particularly in the first few cycles.
DC vaccine formulations:
Injection site reactions are milder (intradermal DCs vs. peptide-adjuvant depots)
Autoimmune manifestations (uveitis, vitiligo) in ~10–15% of patients
Rare: systemic inflammatory responses if large numbers of mature DCs are given IV
TCR-engineered adoptive cell therapy (highest risk):
On-target off-tumor toxicity: is the primary safety concern. The Johnson et al. (2009) trial documented uveitis in 14/20 patients and hearing loss in 10/20 — both caused by CTL attack on melanocytes in the eye and cochlea. Three patients required systemic steroids; two required local steroid injections into the eye.
Cytokine release syndrome: Mild-to-moderate in most ACT trials; severe (grade 3–4) in <10%
Lymphodepletion toxicity: Infections, cytopenias from the conditioning regimen rather than the T-cell product itself
Rare and Theoretical Risks
Immune escape selection: Paradoxically, potent AAGIGILTV-directed vaccination can select for MART-1-negative tumor variants. Several case reports document melanoma recurrence with tumors that have downregulated or deleted MART-1 expression — particularly after high-intensity ACT. This is not a direct adverse effect but represents a failure mode that informs the rationale for multi-epitope approaches.
Bystander autoimmunity: T cells activated by AAGIGILTV vaccination can theoretically provide bystander help for other autoreactive lymphocytes in the tumor microenvironment, potentially exacerbating pre-existing autoimmune conditions. This is largely theoretical in the vaccination context but has been observed in the checkpoint inhibitor combination setting.
Peptide aggregation toxicity: High-concentration AAGIGILTV preparations (particularly at >1 mg/mL in aqueous buffers) can form amyloid-like aggregates. These aggregates are immunologically inert and potentially proinflammatory; proper preparation using DMSO/aqueous dilution protocols minimizes this risk.
Contraindications
For clinical vaccine applications:
HLA-A*02:01 negativity: AAGIGILTV simply won't be presented; vaccination is immunologically futile
Active autoimmune disease: The pro-inflammatory mechanism of AAGIGILTV vaccination can exacerbate pre-existing autoimmunity (rheumatoid arthritis, IBD, etc.)
Active systemic infection: Immune activation from vaccination during infection can be counterproductive
Systemic corticosteroid use: Glucocorticoids suppress the T-cell responses that AAGIGILTV vaccination aims to generate; concurrent use should be avoided
For ACT protocols, additional contraindications include active cardiac disease (IL-2 toxicity), severe pulmonary compromise, and inability to tolerate lymphodepleting chemotherapy.
---
Compared to Alternatives
AAAGIGILTV is one of several well-characterized HLA-A2-restricted melanoma epitopes. Understanding how it compares to alternatives is essential for protocol design.
| Feature | AAGIGILTV (MART-1) | NY-ESO-1(157–165) | gp100(280–288) | MAGE-A3(271–279) |
|---|---|---|---|---|
| Source antigen | Melanocyte differentiation | Cancer-testis | Melanocyte differentiation | Cancer-testis |
| HLA restriction | HLA-A*02:01 | HLA-A*02:01 | HLA-A*02:01 | HLA-A*01 (primarily) |
| Precursor T-cell frequency | Very high (0.1–0.5%) | Low-moderate (0.01–0.05%) | Low (0.01–0.02%) | Very low |
| HLA-A2 binding affinity | Moderate (IC₅₀ ~500 nM) | High (IC₅₀ ~50 nM) | High (IC₅₀ ~30 nM) | High |
| Autoimmune risk | Significant (vitiligo, uveitis) | Low (testis antigen) | Moderate (vitiligo) | Very low |
| Clinical response correlation | Moderate | Moderate | Moderate | Low |
| Expression in melanoma | >90% of tumors | ~40% of tumors | >90% of tumors | ~50% of tumors |
| Antigen loss escape risk | Moderate | Low | Moderate | Low |
| Best application | Combination vaccine; ACT target | Monotherapy vaccine; ACT | Combination vaccine | Multi-tumor vaccine |
The comparison with NY-ESO-1 cancer-testis antigens is instructive. Cancer-testis antigens like NY-ESO-1 are expressed in normal tissues only in the immunologically privileged testes and placenta — meaning CTLs directed against them pose minimal autoimmune risk. However, their lower expression frequency in melanoma (~40%) and the lower precursor T-cell frequency make them harder to immunize against. AAGIGILTV's very high precursor frequency is its major immunological advantage — there are simply more T cells to work with.
For researchers interested in the broader category of vaccine peptides, the SIINFEKL peptide (OVA257–264) serves as the dominant murine model equivalent — used to study T-cell biology in OT-I transgenic mice the same way AAGIGILTV is used to study human melanoma-specific T cells. The CMV-pp65-495-503 epitope provides another useful comparison: like AAGIGILTV, it's HLA-A2-restricted and drives high-frequency T-cell responses, but against a viral rather than tumor antigen.
---
What's Coming Next
Next-Generation AAGIGILTV-Based Strategies
The field has moved well beyond simple peptide-in-adjuvant approaches. Several emerging strategies are actively reshaping how AAGIGILTV is deployed in research and clinical settings.
mRNA neoantigen vaccines incorporating MART-1: Following the success of mRNA COVID-19 vaccines, Moderna and BioNTech have both developed personalized mRNA cancer vaccines that include MART-1/AAGIGILTV as a shared antigen anchor alongside patient-specific neoantigens. The BNT111 product (now in phase II trials combined with pembrolizumab) encodes four melanoma-associated antigens including MART-1, gp100, tyrosinase, and NY-ESO-1 in a single lipid nanoparticle formulation. Early data show AAGIGILTV-specific T-cell responses in >80% of treated patients — substantially higher than historical peptide vaccine rates.
High-affinity TCR engineering: The on-target off-tumor toxicity problem with AAGIGILTV-specific TCRs has driven research into affinity-tuned TCRs — engineered variants with intermediate affinities (Kd ~10–100 μM) that can recognize the high-density pMHC presentation on tumor cells but not the low-density presentation on normal melanocytes. Preclinical data from the Jakobsen group (Oxford) suggest that this affinity window can be identified and exploited, though the therapeutic index remains narrow.
Nanoparticle delivery systems: Several groups are exploring AAGIGILTV loaded onto PLGA nanoparticles or lipid nanoparticles for depot-free subcutaneous or intranodal delivery. Nanoparticle formulations protect the peptide from rapid degradation, enable co-delivery with TLR agonist adjuvants (particularly poly I:C or CpG ODN), and can be engineered to target specific DC subsets via surface ligands. In murine models using human HLA-A2 transgenic mice, nanoparticle-AAGIGILTV generates 3–5-fold higher T-cell responses than peptide-in-IFA.
Bispecific T-cell engagers (BiTEs) incorporating AAGIGILTV pMHC: A conceptually novel approach uses soluble bispecific molecules with one arm binding the HLA-A2/AAGIGILTV pMHC complex on tumor cells and the other binding CD3 on T cells, redirecting polyclonal T cells to kill MART-1-expressing targets regardless of TCR specificity. This approach bypasses the need for vaccination or ex vivo expansion but requires the tumor to express adequate AAGIGILTV/HLA-A2 density.
Outstanding questions the field still needs to answer: What is the minimum AAGIGILTV-specific T-cell frequency required for tumor control? Can the vitiligo/uveitis risk be decoupled from anti-tumor efficacy through careful TCR affinity tuning? Does AAGIGILTV vaccination benefit patients with HLA-A2+ tumors that have downregulated MART-1 expression? How does the gut microbiome composition affect AAGIGILTV vaccine immunogenicity — a question raised by recent data showing microbiome-checkpoint inhibitor interactions? These are the experiments that will define the next decade of MART-1 immunotherapy research.
---
Key Takeaways
AAGIGILTV: (positions 27–35 of MART-1/Melan-A) is the dominant HLA-A*02:01-restricted epitope from melanocyte differentiation antigens, recognized by up to 0.5% of circulating CD8+ T cells in healthy HLA-A2+ adults — among the highest precursor frequencies ever documented for a self-reactive T-cell response.
The peptide works by binding HLA-A*02:01 on antigen-presenting cells, forming a pMHC complex recognized by cytotoxic T lymphocytes that then kill MART-1-expressing melanoma cells via perforin/granzyme B and Fas/FasL pathways.
Wild-type AAGIGILTV binds HLA-A2 with only moderate affinity: (IC₅₀ ~500 nM); the heteroclitic A27L analog (LAGIGILTV) binds ~10-fold more tightly and generates cross-reactive CTLs with superior functional avidity — making it the preferred form for clinical vaccine applications.
Vitiligo development: during AAGIGILTV vaccination is an on-target effect (CTL killing of normal melanocytes) that correlates positively with clinical anti-tumor responses — it functions as a pharmacodynamic biomarker for vaccine efficacy.
DC-pulsed vaccines: consistently outperform peptide-in-adjuvant formulations in immunogenicity; intravenous DC delivery achieves superior T-cell priming compared to intradermal administration in head-to-head comparisons.
TCR-engineered ACT: targeting AAGIGILTV achieves the highest T-cell numbers at the tumor site but carries significant on-target off-tumor risk (uveitis, hearing loss) due to melanocyte expression in the eye and cochlea — observed in 70% of patients in the Johnson 2009 trial.
Multi-epitope vaccination: (AAGIGILTV + gp100 + tyrosinase + CD4 helper epitopes) outperforms single-epitope approaches and reduces the risk of antigen-loss escape variants.
The most promising current strategy combines AAGIGILTV-based vaccination with anti-PD-1 checkpoint blockade — vaccination expands the MART-1-reactive T-cell pool, while checkpoint inhibition restores their function in the immunosuppressive tumor microenvironment.
mRNA vaccine platforms: encoding MART-1 alongside other shared and personalized melanoma antigens are now in phase II trials and showing AAGIGILTV-specific T-cell response rates exceeding 80%.
For in vitro research, AAGIGILTV is used at 1–10 μg/mL for T2 cell pulsing and ELISPOT assays; lyophilized peptide should be stored at -80°C and reconstituted in DMSO before aqueous dilution to prevent aggregation.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---